Osteoarthritis: the impact of a serious diseaseBREEDVELD, F. C.Rheumatology (Oxford. Print). 2004, Vol 43, pp i4-i8, issn 1462-0324, SUP1Article

Osteoarthritis therapy: are there still unmet needs?LAUFER, S.Rheumatology (Oxford. Print). 2004, Vol 43, pp i9-i15, issn 1462-0324, SUP1Article

Safety of anti-inflammatory treatment: new ways of thinkingBRUNE, K.Rheumatology (Oxford. Print). 2004, Vol 43, pp i16-i20, issn 1462-0324, SUP1Article

Acetaminophen selectively suppresses peripheral prostaglandin E₂ release and increases COX-2 gene expression in a clinical model of acute inflammationLEE, Yun-Sil; KIM, Hyungsuk; BRAHIM, Jaime S et al.Pain (Amsterdam). 2007, Vol 129, Num 3, pp 279-286, issn 0304-3959, 8 p.Article

Cyclooxygenase-2 and its role in colorectal cancer developmentWENDUM, Dominique; MASLIAH, Joëlle; TRUGNAN, Germain et al.Virchows Archiv. 2004, Vol 445, Num 4, pp 327-333, issn 0945-6317, 7 p.Article

Current drug therapy for rheumatoid arthritisKAWAI, Shinichi.Journal of orthopaedic science (Print). 2003, Vol 8, Num 2, pp 259-263, issn 0949-2658, 5 p.Conference Paper

The role of COX-2 in oral cancer development, and chemoprevention/treatment of oral cancer by selective COX-2 inhibitors : The administration of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors in dentistryWANG, Z.Current pharmaceutical design. 2005, Vol 11, Num 14, pp 1771-1777, issn 1381-6128, 7 p.Article

Celecoxib pathways: pharmacokinetics and pharmacodynamicsLI GONG; THORN, Caroline F; BERTAGNOLLI, Monica M et al.Pharmacogenetics and genomics (Print). 2012, Vol 22, Num 4, pp 310-318, issn 1744-6872, 9 p.Article

Progress in COX-2 Inhibitors: A Journey So FarCHAKRABORTI, Asit K; GARG, Sanjeev K; KUMAR, Raj et al.Current medicinal chemistry. 2010, Vol 17, Num 15, pp 1563-1593, issn 0929-8673, 31 p.Article

Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitorHASEGAWA, Kiyoshi; OHASHI, Yoshimasa; ISHIKAWA, Kunimi et al.International journal of oncology. 2005, Vol 26, Num 5, pp 1419-1428, issn 1019-6439, 10 p.Article

A randomized crossover trial of tenoxicam compared with rofecoxib for postoperative dental pain controlZACHARIAS, M; DE SILVA, R. K; HERBISON, P et al.Anaesthesia and intensive care. 2004, Vol 32, Num 6, pp 770-774, issn 0310-057X, 5 p.Article

COX inhibitors and breast cancerMAZHAR, D; ANG, R; WAXMAN, J et al.British journal of cancer. 2006, Vol 94, Num 3, pp 346-350, issn 0007-0920, 5 p.Article

Antiviral effect of a selective COX-2 inhibitor on H5N1 infection in vitroLEE, Suki M. Y; GAI, W. W; CHEUNG, Timothy K. W et al.Antiviral research. 2011, Vol 91, Num 3, pp 330-334, issn 0166-3542, 5 p.Article

Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cellsNAGAHARA, Takakazu; OKANO, Jun-Ichi; MURAWAKI, Yoshikazu et al.Oncology reports. 2007, Vol 18, Num 5, pp 1281-1290, issn 1021-335X, 10 p.Article

Selective COX-2 inhibitors. Part 1: Synthesis and biological evaluation of phenylazobenzenesulfonamidesTSAI, Wei-Jern; SHIAO, Young-Ji; LIN, Shwu-Jiuan et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 17, pp 4440-4443, issn 0960-894X, 4 p.Article

Selective COX-2 inhibitors. Part 2. Synthesis and biological evaluation of 4-benzylideneamino-and 4-phenyliminomethyl-benzenesulfonamidesLIN, Shwu-Jiuan; TSAI, Wei-Jern; CHIOU, Wen-Fei et al.Bioorganic & medicinal chemistry. 2008, Vol 16, Num 5, pp 2697-2706, issn 0968-0896, 10 p.Article

The anti-cancer effect of COX-2 inhibitors on gastric cancer cellsCHO, Soo-Jeong; KIM, Nayoung; KIM, Joo Sung et al.Digestive diseases and sciences. 2007, Vol 52, Num 7, pp 1713-1721, issn 0163-2116, 9 p.Article

Prenatal effects of DuP-697-the irreversible, highly selective cyclooxygenase-2 inhibitorBURDAN, Franciszek; DUDKA, Jaroslaw; SZUMILO, Justyna et al.Reproductive toxicology (Elmsford, NY). 2003, Vol 17, Num 4, pp 413-419, issn 0890-6238, 7 p.Article

The effect of nimesulide, a selective cyclooxygenase-2 inhibitor, on Ets-1 and Ets-2 expression in head and neck cancer cell linesLAMM, Wolfgang; VORMITTAG, Laurenz; TURHANI, Dritan et al.Head & neck. 2005, Vol 27, Num 12, pp 1068-1072, issn 1043-3074, 5 p.Article

Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking studyEL-SAYED, Magda A.-A; ABDEL-AZIZ, Naglaa I; ABDEL-AZIZ, Alaa A.-M et al.Bioorganic & medicinal chemistry. 2011, Vol 19, Num 11, pp 3416-3424, issn 0968-0896, 9 p.Article

Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activityABOUZID, Khaled; BEKHIT, Salma A.Bioorganic & medicinal chemistry. 2008, Vol 16, Num 10, pp 5547-5556, issn 0968-0896, 10 p.Article

Synthesis and effects on the COX-1 and COX-2 activity in human whole blood ex vivo of derivatives containing the [1]benzothienol-[3,2-d]pyrimidin-4-one heterocyclic systemSANTAGATI, Andrea; GRANATA, Giuseppe; MARRAZZO, Agostino et al.Archiv der Pharmazie (Weinheim). 2003, Vol 336, Num 9, pp 429-435, issn 0365-6233, 7 p.Article

The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibitionSINGH-RANGER, G; MOKBEL, K.European journal of surgical oncology. 2002, Vol 28, Num 7, pp 729-737, issn 0748-7983, 9 p.Article

Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, ItalyCASTELLSAGUE, Jordi; PISA, Federica; PEREZ-GUTTHANN, Susana et al.Pharmacoepidemiology and drug safety. 2013, Vol 22, Num 4, pp 365-375, issn 1053-8569, 11 p.Article

Synthesis and anti-inflammatory activity of the major metabolites of imrecoxibZHIQIANG FENG; FENGMING CHU; ZONGRU GUO et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 8, pp 2270-2272, issn 0960-894X, 3 p.Article